Podcast: Clinical Challenges in Extrapulmonary NEC: Expert Insights on Diagnosis, Treatment, and Emerging Targets
Tracking # 20-1354299
Course overview
Extrapulmonary neuroendocrine carcinomas, EP-NECs are rare, aggressive tumors with complex diagnostic challenges and limited treatment guidance. This podcast highlights the latest evidence on emerging therapies including targeted agents, checkpoint inhibitors, and radionuclide therapy while exploring multidisciplinary strategies to improve patient outcomes. Stay current on advances shaping the future of EP-NEC care. Start the activity now!
Subject areas
This course counts toward the state boards and subject areas below.
Arkansas State Board of Nursing
Certified Nurse Practitioner
Registered Nurse Practitioner
Kansas State Board of Nursing
Nurse Practitioner
New Hampshire Board of Nursing
Advanced Practice Registered Nurse
New Mexico Board of Nursing
Certified Nurse Practitioner
North Dakota Board of Nursing
Advanced Practice Registered Nurse
South Carolina Board of Nursing
Advanced Practice Registered Nurse
Disclosure statements
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health endorses the standards of the ACCME and ACPE that require everyone in a position to control the content of a CME/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/CPE activity. CME/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Andrew E. Hendifar, MD, discloses that he has served on an advisory board or panel for Alcresta, Exelixis, Merck, and Pfizer.
Danielle Hutchings, MD, has no relevant financial relationships to disclose.
i3 Health has mitigated all relevant financial relationships.